- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
New England Research & Management Inc. Acquires New Stake in Incyte Corporation
The institutional investor bought 17,400 shares of the biopharmaceutical company's stock.
Mar. 22, 2026 at 9:35am
Got story updates? Submit your updates here. ›
New England Research & Management Inc. bought a new position in shares of Incyte Corporation (NASDAQ:INCY) in the fourth quarter, according to the company's disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,400 shares of the biopharmaceutical company's stock, valued at approximately $1,719,000.
Why it matters
This investment by New England Research & Management Inc. in Incyte Corporation, a leading biopharmaceutical company, signals confidence in the company's future prospects and growth potential within the healthcare and pharmaceutical sectors.
The details
New England Research & Management Inc. acquired the new stake in Incyte Corporation during the fourth quarter. The 17,400 shares purchased are valued at approximately $1,719,000. This investment adds to Incyte's institutional ownership, which currently stands at 96.97% of the company's stock.
- New England Research & Management Inc. bought the new position in Incyte Corporation in the fourth quarter.
The players
New England Research & Management Inc.
An institutional investor that acquired a new stake in Incyte Corporation.
Incyte Corporation
A biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation.
The takeaway
This investment by New England Research & Management Inc. in Incyte Corporation reflects the institutional investor's confidence in the biopharmaceutical company's growth prospects within the healthcare sector.
